乳香提取物联合人参皂苷Rb2调控骨质疏松大鼠骨重塑过程的机制研究  

Regulation and mechanism of 3-acetyl-11-keto-β-lactonic acid combined with Ginsenoside Rb2 on bone remodeling process in osteoporosis rats

作　　者：张巍 孙燕[1] 张建萍[1] 郑世军[1] Zhang Wei;Sun Yan;Zhang Jianping;Zheng Shijun(Department of Upper Limb Orthopedics,Zhengzhou Orthopaedics Hospital,Zhengzhou 450022,China)

机构地区：[1]郑州市骨科医院上肢骨科,郑州450022

出　　处：《中华实验外科杂志》2024年第9期2056-2059,共4页Chinese Journal of Experimental Surgery

基　　金：河南省医学科技攻关项目(LHGJ20210795)。

摘　　要：目的 探究乳香提取物3-乙酰基-11-酮基-β-乳香酸(AKBA)联合人参皂苷Rb2对骨质疏松大鼠骨重塑调控过程的分子机制.方法 50只SD大鼠随机分成空白组、模型组、阳性对照组和实验低、高剂量组.模型组,阳性对照组和实验低、高剂量组大鼠按照70mg/(kg·d)剂量给予维A酸溶液灌胃建立大鼠骨质疏松模型,空白组给予10 ml/kg的生理盐水灌胃,连续14 d.阳性对照组给予0.36 mg/(kg·d)戊酸雌二醇灌胃,实验低、高剂量组分别给予[5、20 mg/(kg·d)]AKBA联合人参皂苷Rb2腹腔注射,模型组给予同体积的生理盐水处理,持续8周.采用骨密度(BMD)仪分别测定各组大鼠右股骨的BMD值.蛋白质印迹法(Western blot)检测用药前后大鼠右股骨β-连环蛋白(β-catenin)、Runt相关转录因子2(RunX^(2))、叉头框转录因子01(Fox01)、骨保护素(OPG)和T细胞核因子1蛋白(NFATc1)的蛋白表达水平.组间比较采用两独立样本t检验.结果 双能X射线骨密度仪测定大鼠股骨骨密度显示,建模各组大鼠股骨BMD明显低于空白组(0.685±0.062比0.367±0.038,t=5.314,P<0.01)差异有统计学意义;阳性对照组与实验组大鼠股骨BMD明显高于模型组(0.367±0.038 比 0.584±0.041、0.522±0.034、0.637±0.055,t=4.453、4.216、5.622,P<0.05),差异有统计学意义.Western blot结果显示,与模型组比较,AKBA和人参皂苷Rb2联合用药能增强大鼠股骨 β-catenin(0.453±0.030 比 0.707±0.031、0.728±0.037,t=5.285、6.342,P<0.05)、Runx2(0.272±0.018 比 0.585±0.019、0.672±0.031,t=4.188、5.218,P<0.05)、FoxO1(0.477±0.028 比 0.643±0.028、0.791±0.038,t=5.062、5.844,P<0.05)、OPG(0.436±0.022 比0.676±0.029、0.752±0.031,t=4.726、5.573,P<0.05)蛋白表达量,同时抑制 NFATc1 表达(0.593±0.030 比 0.405±0.025、0.344±0.019,t=4.622、5.276,P<0.05),且用药表现为剂量依赖性(P<0.05).结论 AKBA和人参皂苷Rb2联合用药可能通过作用于Wnt/β-catenin、OPG/NFATc1信号通路促进成骨细胞分化和抑Objective To explore the molecular mechanism of 3-acetyl-11-keto-β-mastic acid(AKBA)combined with ginsenoside Rb2 on bone remodeling in osteoporosis rats.Methods A total of 50 SD rats were randomly divided into blank group,model group,positive control group,and experimental low-dose and high-dose groups.Rats in model group,positive control group and experimental low and high dose groups were given retinoic acid solution at the dose of 70 mg/(kg·d)to establish a rat osteoporosis model,and the blank group was given 10 ml/kg normal saline intragastric administration for 14 days.The positive control group was given 0.36 mg/(kg·d)estradiol valerate by intragastric administration,the ex-perimental low dose and high dose groups were given different doses[5,20 mg/(kg·d)]of AKBA com-bined with ginsenoside Rb2 intraperitoneal injection,and the model group was given the same volume of normal saline treatment for 8 weeks.Bone mineral density(BMD)values of right femur in each group were measured by BMD meter.The protein expression levels ofβ-catenin,Runt-related transcription factor 2(RunX^(2)),forkhead box protein O1(FoxO1),osteoprotegerin(OPG)and nuclear factor of activated T cells c1(NFATc1)in the right femur of rats before and after treatment were detected by Western blotting.Two independent samples t test was used for comparison between groups.Results Compared with the blank group,the BMD of the femur in the modeling group was significantly decreased(0.685±0.062 vs.0.367±0.038,t=5.314,P<0.01).Compared with model group,the femur BMD of positive control group and experimental group was significantly increased(0.367±0.038 vs.0.584±0.041,0.522±0.034,0.637±0.055,t=4.453,4.216,5.622,P<0.05).Western blotting analysis showed that com-pared with model group,AKBA combined with ginsenoside Rb2 could enhanceβ-catenin of rat femur(0.453±0.030 vs.0.707±0.031,0.728±0.037,t=5.285,6.342,P<0.05),Runx2(0.272±0.018 vs.0.585±0.019,0.672±0.031,t=4.188,5.218,P<0.05),FoxO1(0.477±0.028 vs.0.643±0.028,0.791±0.038,t=5.062,5.84

关 键 词：骨质疏松症 3-乙酰基-11-酮基-β-乳香酸 人参皂苷Rb2 骨重塑 

分 类 号：R285[医药卫生—中药学]